Trending: Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal

Dow Jones05-13

10:00 ET -- Fulcrum Therapeutics is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Fulcrum Therapeutics has licensed the international rights to its proposed treatment for a rare, genetic muscular disorder to France's Sanofi in a deal potentially worth more than $1 billion to the clinical-stage biopharmaceutical company. Fulcrum said it will work with Sanofi on the development and commercialization of losmapimod. The agreement gives Sanofi exclusive commercialization rights for losmapimod outside the U.S., while Fulcrum, based in Cambridge, Mass., retains full U.S. commercialization rights. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)

(END) Dow Jones Newswires

May 13, 2024 10:00 ET (14:00 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2435737542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-13 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2435737542","market":"sh","top_or_hot":-1,"title":"Trending: Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  10:00 ET -- <a href=\"https://laohu8.com/S/FULC\">Fulcrum Therapeutics</a> is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Fulcrum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> has licensed the international rights to its proposed treatment for a rare, genetic muscular disorder to France's <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> in a deal potentially worth more than $1 billion to the clinical-stage biopharmaceutical company. Fulcrum said it will work with Sanofi on the development and commercialization of losmapimod. The agreement gives Sanofi exclusive commercialization rights for losmapimod outside the U.S., while Fulcrum, based in Cambridge, Mass., retains full U.S. commercialization rights. Dow Jones &amp; Co. owns Factiva. (chris.wack@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2024 10:00 ET (14:00 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Trending: Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTrending: Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-13 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>10:00 ET -- Fulcrum Therapeutics is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Fulcrum Therapeutics has licensed the ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2435737542","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2435737542","pubTimestamp":1715608800,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"10:00 ET -- Fulcrum Therapeutics is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Fulcrum Therapeutics has licensed the international rights to its proposed treatment for a rare, genetic muscular disorder to France's Sanofi in a deal potentially worth more than $1 billion to the clinical-stage biopharmaceutical company. Fulcrum said it will work with Sanofi on the development and commercialization of losmapimod. The agreement gives Sanofi exclusive commercialization rights for losmapimod outside the U.S., while Fulcrum, based in Cambridge, Mass., retains full U.S. commercialization rights. Dow Jones & Co. owns Factiva. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","FULC":"Fulcrum Therapeutics","SNYNF":"Sanofi","BK4585":"ETF&股票定投概念","BK4588":"碎股","SNY":"赛诺菲安万特"},"translate_title":"趋势：Fulcrum Therapeutics，赛诺菲在Losmapimod许可协议中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FULC":1,"SNYNF":1,"SNY":0.9},"content_text":"10:00 ET -- Fulcrum Therapeutics is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. Fulcrum Therapeutics has licensed the international rights to its proposed treatment for a rare, genetic muscular disorder to France's Sanofi in a deal potentially worth more than $1 billion to the clinical-stage biopharmaceutical company. Fulcrum said it will work with Sanofi on the development and commercialization of losmapimod. The agreement gives Sanofi exclusive commercialization rights for losmapimod outside the U.S., while Fulcrum, based in Cambridge, Mass., retains full U.S. commercialization rights. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2024 10:00 ET (14:00 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2435737542"}